CIK 0001847367 · <br>Emerging growth company
ALUMIS INC.
Sign in to watch- Ticker
- ALMS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 650-231-6625
- Business address
- 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, 94080
- Former names
- FL2021-001, Inc.
- Open-market buys, last 90 days
- $10,726,255
- in 1 filing
- Open-market sales, last 90 days
- $1,037,650
- in 7 filings
Net +$9,688,605. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- AKKARAJU SRINIVAS +$9.7M Director sold 4% of stake
- Schroer John R. −$5K Chief Financial Officer sold 3% of stake
- Hardiman Roy C. −$4K Chief Business & Strategy Ofcr sold <1% of stake
- Goldstein David M −$4K Chief Scientific Officer sold 2% of stake
- Bradley Mark Christopher −$4K Chief Development Officer sold 1% of stake
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-07-01 | Bradley Mark Christopher Chief Development Officer | Returned to the company | −20,026 | 0 | ||
| 2024-07-01 | Bradley Mark Christopher Chief Development Officer | Grant or award | +20,026 | 20,026 | ||
| 2024-07-01 | Bradley Mark Christopher Chief Development Officer | Returned to the company · Stock Option (Right to Buy) | −4,278 | 0 | ||
| 2024-07-01 | Bradley Mark Christopher Chief Development Officer | Grant or award · Stock Option (Right to Buy) | +4,278 | 4,278 | ||
| 2024-07-01 | Bradley Mark Christopher Chief Development Officer | Returned to the company · Stock Option (Right to Buy) | −130,481 | 0 | ||
| 2024-07-01 | Bradley Mark Christopher Chief Development Officer | Grant or award · Stock Option (Right to Buy) | +130,481 | 130,481 | ||
| 2024-07-01 | Bradley Mark Christopher Chief Development Officer | Returned to the company · Stock Option (Right to Buy) | −128,342 | 0 | ||
| 2024-07-01 | Bradley Mark Christopher Chief Development Officer | Grant or award · Stock Option (Right to Buy) | +128,342 | 128,342 | ||
| 2024-07-01 | Bradley Mark Christopher Chief Development Officer | Returned to the company · Stock Option (Right to Buy) | −12,834 | 0 | ||
| 2024-07-01 | Bradley Mark Christopher Chief Development Officer | Grant or award · Stock Option (Right to Buy) | +12,834 | 12,834 | ||
| 2024-07-01 | Bradley Mark Christopher Chief Development Officer | Returned to the company · Stock Option (Right to Buy) | −23,093 | 0 | ||
| 2024-07-01 | Bradley Mark Christopher Chief Development Officer | Grant or award · Stock Option (Right to Buy) | +23,093 | 23,093 | ||
| 2024-07-01 | Bradley Mark Christopher Chief Development Officer | Returned to the company · Stock Option (Right to Buy) | −155,304 | 0 | ||
| 2024-07-01 | Bradley Mark Christopher Chief Development Officer | Grant or award · Stock Option (Right to Buy) | +155,304 | 155,304 | ||
| 2024-07-01 | Bradley Mark Christopher Chief Development Officer | Returned to the company · Stock Option (Right to Buy) | −53,475 | 0 | ||
| 2024-07-01 | Bradley Mark Christopher Chief Development Officer | Grant or award · Stock Option (Right to Buy) | +53,475 | 53,475 | ||
| 2024-07-01 | Babler Martin President, CEO and Chairman | Returned to the company | −90,804 | 0 | ||
| 2024-07-01 | Babler Martin President, CEO and Chairman | Grant or award | +90,804 | 90,804 | ||
| 2024-07-01 | Babler Martin President, CEO and Chairman | Returned to the company · Stock Option (Right to Buy) | −21,390 | 0 | ||
| 2024-07-01 | Babler Martin President, CEO and Chairman | Grant or award · Stock Option (Right to Buy) | +21,390 | 21,390 |
Page 19 of 21 · 405 trades